Van ECK Associates Corp Has $115.47 Million Holdings in Johnson & Johnson (NYSE:JNJ)

Van ECK Associates Corp grew its position in shares of Johnson & Johnson (NYSE:JNJ) by 2.3% in the 4th quarter, Holdings Channel reports. The institutional investor owned 798,414 shares of the company’s stock after acquiring an additional 18,228 shares during the period. Van ECK Associates Corp’s holdings in Johnson & Johnson were worth $115,466,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Louisbourg Investments Inc. increased its position in Johnson & Johnson by 6.8% during the fourth quarter. Louisbourg Investments Inc. now owns 47,702 shares of the company’s stock worth $6,899,000 after buying an additional 3,055 shares during the last quarter. Retirement Guys Formula LLC increased its holdings in shares of Johnson & Johnson by 5.3% during the 4th quarter. Retirement Guys Formula LLC now owns 5,921 shares of the company’s stock valued at $856,000 after acquiring an additional 299 shares during the last quarter. Avion Wealth raised its stake in shares of Johnson & Johnson by 31.5% in the 4th quarter. Avion Wealth now owns 1,052 shares of the company’s stock valued at $152,000 after acquiring an additional 252 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in Johnson & Johnson by 20.5% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 544,291 shares of the company’s stock worth $78,389,000 after purchasing an additional 92,693 shares during the last quarter. Finally, Avidian Wealth Enterprises LLC boosted its position in Johnson & Johnson by 2.0% during the fourth quarter. Avidian Wealth Enterprises LLC now owns 17,092 shares of the company’s stock worth $2,472,000 after purchasing an additional 343 shares during the period. Institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

JNJ has been the topic of a number of recent analyst reports. Morgan Stanley dropped their price target on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 23rd. Leerink Partners cut their target price on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Argus raised Johnson & Johnson to a “strong-buy” rating in a research report on Friday, January 24th. Wells Fargo & Company cut their price objective on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a research report on Thursday, January 23rd. Finally, Barclays raised their target price on Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a report on Tuesday, January 28th. Nine analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $170.67.

Insider Buying and Selling

In other news, Director Mark A. Weinberger acquired 1,000 shares of the firm’s stock in a transaction on Thursday, December 12th. The shares were purchased at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the purchase, the director now owns 1,000 shares of the company’s stock, valued at $147,220. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $156.20 on Friday. The stock has a market cap of $376.08 billion, a P/E ratio of 23.49, a PEG ratio of 2.46 and a beta of 0.52. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $168.85. The company’s 50-day simple moving average is $147.87 and its 200 day simple moving average is $156.00.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. The business had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. Johnson & Johnson’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.29 EPS. As a group, research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be issued a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.18%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s payout ratio is 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.